$ARCT

Arcturus Therapeutics (ARCT) will present Phase 2 clinical data for ARCT-810, a treatment for Ornithine Transcarbamylase (OTC) deficiency, on September 23, 2026. The company's mRNA liver therapeutics platform will also be discussed. ARCT-810 has received Orphan Drug and Fast Track designations from the FDA. OTC deficiency affects approximately 10,000 people in Europe and the U.S.

Arcturus Therapeutics (ARCT), MediciNova (MNOV), Inovio (INO), and Eyepoint Pharmaceuticals (EYPT) have upcoming binary events. ARCT has Phase II OTC-deficiency data and a Q4 cystic-fibrosis decision. MNOV expects Phase II data in September and COMBAT-ALS readout by year-end. INO awaits an FDA decision on INO-3107 in October. EYPT anticipates LUCIA Phase III data in Q4. All face significant binary risk.

Arcturus Therapeutics (ARCT) shares rose 10.7% after announcing participation in five investor conferences in September 2026, signaling confidence in its pipeline. The company has a cash position of $191M and a strategic collaboration with Thermo Fisher. Analysts maintain a Buy rating, and the stock hit a session high of $16.45, despite broader market declines.

Arcturus Therapeutics (ARCT) shares surged over 60% this week, driven by sector-wide enthusiasm for mRNA technology and company-specific progress. The rally began after positive late-stage results from Merck and Moderna's mRNA cancer vaccine. ARCT's pipeline focuses on rare diseases, with key trials expected to report data in 2026. The company recently regained full rights to its COVID vaccine, KOSTAIVE, and has a solid balance sheet. Despite recent challenges, retail sentiment has turned extrem

Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.

Moderna (MRNA) and Merck (MRK) announced a cancer vaccine, boosting their market caps by $44B and $13B respectively. Moderna's stock surged 177%, while BioNTech (BNTX) and Arcturus (ARCT) also saw gains of 22% and 25%.

Arcturus Therapeutics (ARCT) reported Q2 2026 revenue of $3M ($5M for six months) versus $28.3M and $57.7M a year earlier, citing lower recognition tied to the CSL Seqirus collaboration termination process. Net loss was $23.8M ($0.84/share). Cash was $191.5M, with a runway through 2028. Company regained global rights to KOSTAIVE and received a $12M one-time payment. Phase II ARCT-032 enrollment continues, with a Phase III decision expected in Q4 2026.

Arcturus Therapeutics (Nasdaq: ARCT) terminated its sa-mRNA vaccine partnership with CSL Seqirus via a settlement. Arcturus regained global rights to KOSTAIVE (ARCT-154) and other vaccine programs. CSL Seqirus will pay $12m cash, and Arcturus is released from about $16m in R&D credits, totaling about $28m. The deal unwinds a pact valued around $4.3b.

Arcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrollment and dosing completed; d

Arcturus Therapeutics (ARCT) shares rose 7.84% to $7.43 on Nasdaq after the company said it entered a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis. Thermo Fisher will provide manufacturing, clinical research and commercialization support via its Accelerator platform, with exclusive commercial manufacturing rights if approved.